ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02564198
Recruitment Status : Recruiting
First Posted : September 30, 2015
Last Update Posted : April 24, 2018
Sponsor:
Collaborator:
Children's Oncology Group
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : January 2019
  Estimated Study Completion Date : January 2019